How to Find a Ketamine Clinic Near You: The Complete 2026 Patient Guide

The U.S. ketamine clinic market has grown from fewer than 100 clinics in 2015 to more than 1,500 by 2024, with an estimated market value of $3.4 billion. But no federal standard governs how these clinics operate, no board certification in ketamine therapy exists, and the authors of the most authoritative clinical guidance document — the 2017 APA Consensus Statement — estimated that fewer than 5% of ketamine providers met their recommended standards at the time of publication.

That gap between the number of clinics and the number of good clinics is the problem this guide solves. Here's exactly what to look for, what to ask, and what should send you to the next provider on your list.

Section 1: What Credentials Actually Matter (and What Doesn't Exist)

The first thing to understand: there is no ABMS board certification specific to ketamine therapy. The American Board of Medical Specialties, which oversees all recognized medical board certifications in the U.S., has not sanctioned any ketamine-specific certification. Any clinic claiming a provider is "board-certified in ketamine" is using a phrase with no recognized medical meaning.

The American Board of Ketamine Physicians (ABKP) administers its own voluntary exam and directory at abkp.org, but it is not an ABMS member board and lacks the institutional recognition of standard medical board certifications.

What actually signals relevant expertise

The board certifications that matter are proxies for the knowledge ketamine requires:

ABPN psychiatry certification — deep knowledge of mental health diagnosis, psychopharmacology, and patient selection. Critical for psychiatric ketamine use.
ABA anesthesiology certification — expertise in ketamine's pharmacology, airway management, sedation management, and hemodynamic monitoring.
ABEM emergency medicine certification — ACLS training and advanced airway skills.
Pain medicine subspecialty certification (jointly sponsored by ABA, ABPN, and ABPMR) — relevant for chronic pain ketamine protocols.

The 2017 APA Consensus Statement, published in JAMA Psychiatry by Sanacora et al., remains the field's most authoritative clinical guidance. It recommends providers be licensed clinicians who can administer DEA Schedule III medications, hold Advanced Cardiac Life Support (ACLS) certification, have received didactic training on ketamine pharmacology, and have direct supervised clinical experience administering ketamine.

Recognized training programs

Several specialized programs have built meaningful track records:

ASKP3 (American Society of Ketamine Physicians, Psychotherapists & Practitioners) — Founded 2016, over 500 multidisciplinary members. Publishes the most widely referenced voluntary standards ("Standards of Practice in the Therapeutic Use of Subanesthetic Ketamine," 2020). Launched a Pledge Program in December 2024 requiring annual commitment to basic administration standards. Maintains a publicly searchable provider directory at askp.org/directory. Led by psychiatrist Dr. Sandhya Prashad.

Ketamine Research Foundation / Ketamine Training Center — Founded by Dr. Phil Wolfson, MD. Has trained over 1,000 practitioners since 2018 through 5–6 day residential experiential retreats. Provides 30 AMA Category I credits.

Polaris Insight Center — Based in San Francisco, founded by MAPS-trained clinicians. Offers a 1–2 year KAP Practitioner Certificate Program; APA-approved CE provider.

Integrative Psychiatry Institute (IPI) — 6-module online training with 50 AMA PRA Category 1 Credits.

MD/DO-led vs. NP/PA-led clinics

No published comparative outcome studies exist specifically comparing MD/DO-led versus NP/PA-led ketamine clinics. Any DEA-registered provider with prescriptive authority for Schedule III substances can legally prescribe ketamine — this includes MDs, DOs, PAs, NPs, and CRNAs in most states. However, some states require physician supervision specifically for IV ketamine administration even where NPs have independent practice authority for other substances. The APA Consensus Statement recommends MD/DO-level training as the baseline.

Section 2: 10 Questions to Ask Before Booking

These questions separate clinics with genuine clinical rigor from those optimizing for throughput.

1. "What is your screening and evaluation process before treatment?"

This is the single most important question. A clinic willing to treat anyone without thorough medical and psychiatric evaluation is a major red flag. Reputable clinics require comprehensive psychiatric history, physical health assessment, current medication review, substance use history, and documentation of treatment-resistant status — typically failure of at least two adequate antidepressant trials at adequate doses for at least six weeks.

2. "Do you offer same-day treatment appointments?"

No reputable clinic provides treatment before thorough evaluation. If the answer is yes, move on.

3. "What vital signs do you monitor, and how often?"

Blood pressure, heart rate, and oxygen saturation should be monitored continuously throughout IV infusions — not just at the start and end. Continuous monitoring is standard of care.

4. "Who will be present with me during the infusion?"

Patients are in a dissociative, vulnerable state during treatment. Understand who is in the room and what their role is.

5. "What emergency certifications does your staff hold?"

BLS (Basic Life Support) is the minimum. ACLS (Advanced Cardiac Life Support) is the standard to look for. This matters because ketamine elevates blood pressure and heart rate, and adverse cardiovascular events, though rare, require a prepared response.

6. "How many patients have you treated?"

100+ patients treated is a reasonable experience threshold. ASKP3 considers 2+ years of clinic operation to indicate established expertise.

7. "Do you offer integration therapy or psychotherapy support?"

This question distinguishes comprehensive care from what patients call "shoot and scoot" clinics. Research consistently shows ketamine paired with integration therapy produces deeper, longer-lasting improvements. Ketamine creates a window of neuroplasticity in the 24–48 hours post-infusion — clinics that ignore this are leaving the most important part of treatment on the table.

8. "How do you measure whether treatment is working?"

Good clinics track outcomes using validated assessment tools. The answer should include instruments like the PHQ-9 (depression) and GAD-7 (anxiety). If the clinic has no formal outcome measurement, they have no evidence base to support their results.

9. "What happens if ketamine doesn't work for me?"

A thoughtful answer includes discussion of alternatives: TMS (transcranial magnetic stimulation), ECT (electroconvulsive therapy), medication adjustments, or referral to a specialist. Clinics that treat ketamine as the only answer are not operating as comprehensive mental health providers.

10. "Can I see your informed consent form before scheduling?"

Written informed consent covering off-label use is non-negotiable. Any hesitation to share this document before you commit to treatment is a concern.

Section 3: Red Flags That Should Make You Walk Away

Legitimate oversight bodies and experienced clinicians have identified these warning signs through years of watching the industry develop:

No mental health professional involved in care — psychiatric patient selection is a clinical skill; ketamine without it is pharmacologically reckless
No screening for substance use, psychosis, or cardiovascular conditions — these are not optional; active psychosis, uncontrolled hypertension, and substance use disorder are absolute contraindications
No vital sign monitoring during administration — substandard care by any clinical benchmark
Same-day treatment without evaluation — documented as a red flag in the APA standards
"Secret formulations" or "proprietary blends" — explicitly called out by ASKP3 as a warning sign; ketamine dosing is not a trade secret
No written informed consent covering off-label status
Aggressive miracle-cure marketing — ketamine real-world response rates in VA data are 26% (≥50% PHQ-9 improvement) and 15% remission by week six, significantly below the 70–85% often cited from controlled research settings
Daily dosing protocols without evidence base — concerns cited for services like Joyous ($129/month for daily low-dose troches) where the long-term safety data for daily ketamine use is not established
Prices dramatically below $400/session for IV ketamine — may indicate inadequate staffing, monitoring, or clinical oversight
No PDMP (Prescription Drug Monitoring Program) checks — a basic safeguard against diversion

The FDA warning and the Perry case

In October 2023, the FDA issued a safety warning about compounded ketamine products, emphasizing that these products have not been evaluated for safety, effectiveness, or quality. The warning cited a patient who experienced respiratory depression after taking compounded oral ketamine at home, with blood levels approximately twice the level used for general anesthesia.

That same month, Matthew Perry died. His autopsy revealed a blood ketamine level of 3,540 ng/mL — approximately 24 times higher than typical therapeutic IV ketamine levels. His case involved illicit, unsupervised, massive-dose use rather than clinical treatment, but the subsequent criminal prosecutions (Dr. Salvador Plasencia sentenced to 30 months in federal prison in December 2025; drug supplier Jasveen Sangha pleading guilty to distribution resulting in death) intensified regulatory scrutiny across the entire ketamine landscape.

Platforms with documented failures

Dr. Smith's / Smith Family MD — Closed after the DEA suspended Dr. Scott Smith's controlled substance prescribing privileges in May 2023. Smith had obtained medical licenses in 49 states to prescribe ketamine nationally at $250/month via telehealth. Thousands of patients were displaced.

Peak Health Global — Closed in approximately September 2022. Faced criticism for TikTok-driven marketing and an intake questionnaire that did not ask about benzodiazepines or alcohol use.

Mindbloom — Still operating as the largest at-home platform (~35 states, claiming nearly 600,000 at-home dosing sessions since 2019), but a wrongful death lawsuit was filed in October 2025 on behalf of Phillip Ward, 27, who died from "ketamine toxicity in the presence of hypertension." The lawsuit alleges Ward had documented hypertension, tachycardia, and substance use disorder that should have immediately disqualified him, and that the blood pressure cuff in his kit was found unused in original packaging.

Section 4: The Four Treatment Settings

Understanding which modality you're considering shapes everything — cost, coverage, and what to look for in a provider. For detailed pricing data, see our ketamine therapy cost guide.

IV ketamine infusion is the most studied modality. Standard protocol: 0.5 mg/kg infused over 40 minutes, 100% bioavailability, private room with monitoring. Cost: $400–$1,000+ per session nationally (IQR $425–$750), with NYC and LA reaching $1,400. Initial 6–8 infusion series: $2,400–$6,000+. Generally not covered by insurance.

Spravato (esketamine nasal spray) is the only FDA-approved ketamine-type treatment for depression. Requires REMS certification, in-office administration with a mandatory 2-hour monitoring period, and patients cannot drive until the next day. Approved as monotherapy for depression in January 2025. Most major commercial insurers cover it with prior authorization. For more on how IV ketamine and Spravato compare clinically, see our ketamine vs. Spravato breakdown.

IM (intramuscular) ketamine offers 93% bioavailability with faster onset (1–5 minutes) than IV. Sessions run shorter overall and cost $275–$400 per session — typically $100–$200 less than IV. The key tradeoff: once injected, the dose cannot be titrated mid-session as it can with IV.

Oral/sublingual ketamine (troches, lozenges) has the lowest bioavailability at 24–32% sublingual and just 7–24% if swallowed. Medication cost: $50–$100/month from the pharmacy, separate from consultation fees. This is the formulation used by all at-home telehealth platforms. The FDA's October 2023 warning specifically addressed compounded oral ketamine. A March 2026 analysis by researcher Michael Alvear, published in STAT News, of six months of Reddit posts across r/TherapeuticKetamine and r/KetamineTherapy found that only 18–20% of analyzed oral ketamine users reported purely positive experiences, with 38–43% reporting clearly negative outcomes.

Section 5: Finding a Clinic in Your State

California

California enforces the Corporate Practice of Medicine (CPOM) doctrine, requiring physician ownership of ketamine clinics. The state is one of the largest markets in the country — major metro areas (Los Angeles, San Francisco, San Diego, Sacramento) all have multiple providers. LA and SF clinics typically charge $600–$800+ per IV session, with some premium facilities exceeding $1,000. Medi-Cal covers Spravato. Verify provider licenses at mbc.ca.gov.

Find California ketamine clinics →

New York

New York also enforces CPOM. In May 2025, the NYSDOH finalized amendments requiring in-person medical evaluation before prescribing controlled substances, with an exception for compliance with federal telehealth rules — meaning the DEA's waiver keeps remote prescribing legal through 2026. NYC IV infusions range $475–$750+ per session. The NYSHIPP/Empire Plan covers Spravato without prior authorization. Verify licenses at op.nysed.gov.

Find New York ketamine clinics →

Colorado

Colorado operates under a relatively permissive regulatory framework. Klarisana alone performed nearly 20,000 ketamine treatments in the state last year. The psilocybin crossover is significant: Proposition 122 passed in November 2022, creating the Regulated Natural Medicine Access Program, with psilocybin healing centers rolling out through 2025–2026. Some providers already offer ketamine-assisted therapy and plan to add psilocybin services. Learn about Colorado's psilocybin program →

Find Colorado ketamine clinics →

Minnesota

Minnesota has no state-specific ketamine regulations beyond standard federal requirements. Twin Cities metro providers include Minnesota Ketamine Clinic (Woodbury), Institute for Integrative Therapies (Eden Prairie), and Psych North serving northern Minnesota. IV infusions run $400–$650/session with 6-infusion packages at $2,400–$3,600. Multiple Spravato-certified REMS centers operate in the metro area. Verify licenses at mn.gov/boards/medical-practice/.

Find Minnesota ketamine clinics →

Texas

Texas maintains relatively open prescribing practices. The state's SB 2308, signed by Governor Greg Abbott in June 2025, allocated $50 million in state matching funds for FDA-regulated clinical trials of ibogaine to treat opioid use disorder, PTSD, and TBI — the largest state-funded psychedelic research initiative in U.S. history. UT Health Houston was selected to lead the research consortium. Major ketamine providers include Klarisana (multiple centers), Neuroglow (Dallas), and Nura Therapy (Fort Worth). Verify licenses at tmb.state.tx.us.

Find Texas ketamine clinics →

Oregon

Oregon has the most developed psilocybin crossover of any state. Under Measure 109, 21 licensed psilocybin service centers, 10 manufacturing facilities, and 329 licensed facilitators were operating as of the program's first-year report. Oregon's psilocybin program is "supported adult use," not medical therapy — service centers cannot operate within healthcare facilities. This creates a structural separation from ketamine medical practices, though individual practitioners may hold both a ketamine medical license and a psilocybin facilitator license. Verify licenses at omb.oregon.gov.

Find Oregon ketamine clinics →

Section 6: What to Expect at Your First Appointment

Screening

Before your first infusion, expect a comprehensive intake covering: complete psychiatric history (diagnoses, previous treatments, documented treatment-resistant status), physical health assessment (cardiovascular, liver, kidney, respiratory), current medication review, substance use history, and family history of psychosis. Many clinics require documentation of treatment-resistant depression — failure of at least two antidepressant medications of different classes at adequate dosages for at least six weeks. Drug screening via urine test is standard.

Critical medication interactions to discuss: Benzodiazepines reduce the duration of ketamine's antidepressant effect and at high doses can abolish the response entirely. Lamotrigine may antagonize ketamine's effects in some patients. MAOIs carry a theoretical risk of hypertensive crisis. Memantine blocks ketamine's effects directly, rendering treatment largely ineffective. Naltrexone may reduce both antidepressant and anti-suicidal effects. SSRIs and SNRIs are generally safe to continue.

Absolute contraindications include: uncontrolled hypertension, active psychosis or schizophrenia, active manic episodes, severe unstable cardiovascular disease, known ketamine allergy, pregnancy, active substance use disorder, and severe hepatic impairment.

Day of your first IV infusion

Fast 4–8 hours beforehand and arrange a ride home — you cannot drive for the remainder of the day.

A small IV line is placed, and ketamine is administered via pump at a controlled rate (typically 0.5 mg/kg for mood disorders) over 40–60 minutes in a private room. Expect dim lighting, a reclining chair, and an eye mask and headphones if you want them.

Physical effects during the infusion include warmth, tingling, mild euphoria, possible nausea, and elevated blood pressure. Psychological effects include dissociation, dream-like thinking, visual distortions, and altered time perception. You remain conscious throughout.

Post-infusion, dissociation typically subsides within minutes. Observation continues for 30–60 minutes until vitals stabilize. Total appointment: approximately 1.5–2 hours.

Course of treatment and what happens after

The standard initial course is 6 infusions over 2–3 weeks. By the third infusion, clinicians can usually assess whether treatment is producing results. After the initial series, maintenance boosters range from every 3 weeks to once a year depending on individual response, with every 4–12 weeks being most common.

Integration therapy — incorporating insights from ketamine sessions through journaling, psychotherapy, and behavioral change — is increasingly recognized as the essential companion to the medicine itself. Ketamine opens a window of neuroplasticity in the 24–48 hours post-infusion when the brain is most receptive to forming new neural connections and thought patterns. Clinics that offer integration support are using that window; clinics that don't are not.

Section 7: How to Verify a Provider Before Booking

State medical board license verification:

California: mbc.ca.gov
New York: op.nysed.gov
Colorado: dpo.colorado.gov
Minnesota: mn.gov/boards/medical-practice/
Texas: tmb.state.tx.us
Oregon: omb.oregon.gov

For a national search, DocInfo.org — maintained by the Federation of State Medical Boards — provides professional background on nearly one million licensed doctors.

For Spravato specifically: REMS certification can be confirmed at spravatorems.com or by calling 1-855-382-6022 (Monday–Friday, 8AM–8PM ET). Only certified healthcare settings may administer Spravato.

Provider directories:

ASKP3 provider directory at askp.org/directory — member-led clinics whose providers have committed to ASKP3's ethical practice standards
PsychedelicBeacon.com — 750+ verified clinic listings with pricing data and provider comparisons, searchable by city, state, and treatment type

Frequently Asked Questions

Is ketamine therapy FDA-approved?

No — not for psychiatric indications. Ketamine has FDA approval as an anesthetic, and its use for depression, PTSD, and anxiety is off-label. The exception is Spravato (esketamine nasal spray), which received FDA approval specifically for treatment-resistant depression and major depressive disorder with suicidal ideation. Spravato was approved as a standalone monotherapy in January 2025.

Does insurance cover ketamine therapy?

Spravato does, with prior authorization, from most major commercial insurers (UnitedHealthcare, Anthem BCBS, Aetna, Cigna, Humana, Medicare Part B). The Janssen WithMe Savings Program can reduce copays to $10/session for eligible commercially insured patients. IV and IM ketamine are generally not covered for mental health indications. HSA and FSA funds can typically be used for all ketamine treatments. CareCredit and Advance Care Card offer 0% APR financing options widely accepted at clinics.

How quickly does ketamine work?

Often rapidly — improvement within hours or days, sometimes after the first infusion. This speed of response is one of ketamine's most clinically significant features, particularly for patients with suicidal ideation. The standard approach is to assess whether treatment is working after three infusions before completing the full initial series.

Is at-home ketamine safe?

At-home oral ketamine uses lower doses and has substantially lower bioavailability (24–32% sublingual vs. 100% IV) than clinic-administered treatment. The FDA's October 2023 warning specifically flagged compounded ketamine products, noting that adverse events from 503A compounding pharmacies are "generally" not reported, meaning the true scope of harm is unknown. The absence of direct medical monitoring is the central safety concern. The STAT News analysis of patient Reddit communities found that only 18–20% of at-home oral ketamine users reported purely positive experiences.

How do I find a ketamine clinic near me?

Search PsychedelicBeacon.com's directory of 750+ verified clinics by city, state, or treatment type, with pricing data from 99+ clinics who publish their rates. Filter by modality (IV, Spravato, IM, oral, KAP), insurance acceptance, and financing options.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making treatment decisions.